Introduction
BrightGene Bio-Medical Technology Co., Ltd. is a research-driven pharmaceutical company dedicated to the R&D and manufacturing of innovative medicines, as well as specialized generic APIs and FDFs. With strong development capabilities, world-class production systems, and robust commercialization expertise, BrightGene provides high-quality products and technical services to global customers. The company’s cGMP-compliant facilities are approved by regulatory authorities such as the USFDA, EU, PMDA, KFDA, and CFDA, demonstrating its commitment to international quality standards.
CSSD/IBCC Support
As Southeast Asia rapidly emerges as a vital market in the global pharmaceutical landscape, driven by economic growth and increasing medical demand, BrightGene recognized the region’s immense potential. With the support of CSSD and the International Business Cooperation Center (IBCC), BrightGene successfully established its Innovation Center in Singapore. CSSD/IBCC played a crucial role in facilitating our soft landing — from site selection and business registration to operational consolidation. This strategic partnership enabled us to swiftly navigate the local business environment and lay a strong foundation for our regional expansion.
 |
 |
Conclusion
The establishment of the Innovation Center in Singapore is a key milestone in BrightGene’s internationalization journey. It underscores our commitment to “going global” with our innovative research and development, accelerating the transformation of our achievements into high-quality products that address unmet clinical needs worldwide. Singapore’s dynamic ecosystem and CSSD’s unwavering support have been instrumental in this endeavor, and we hope our success story inspires other Chinese companies looking to expand their footprint overseas.